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1. Introduction 
The Global Strategy for the Diagnosis, Management and Prevention of COPD guidelines 
(GOLD, 2010) and the UK National Institute of Clinical Excellence guidelines (NICE, 2010) 
recommend an early diagnosis of Chronic Obstructive Pulmonary Disease (COPD) in any 
patient over the age of 35 who has chronic cough (present intermittently or every day 
throughout the day), chronic sputum production, shortness of breath (dyspnoea), frequent 
winter ‘bronchitis’ or wheeze and/or a history of exposure to disease risk factors. 
COPD is a progressive, but preventable and treatable disease, characterised by airflow 
limitation, that is not fully reversible and an abnormal inflammatory response of the lungs 
to noxious particles or gases; COPD is associated with significant extrapulmonary effects 
and comorbidities that may affect the severity (GOLD, 2010). COPD is a complex disease, a 
combination of emphysema and chronic bronchitis, although only one of these may be 
present in some people.  
 Emphysema is characterized by abnormal permanent enlargement of the air spaces 
distal to the terminal bronchioles, accompanied by destruction of their walls, and 
without obvious fibrosis.  
 Chronic bronchitis is characterized by chronic cough or mucous production for at least 
3 months in at least 2 successive years when other causes of chronic cough have been 
excluded (GOLD, 2010).  
The typical symptoms are cough, with large amounts of mucus, wheezing, shortness of 
breath, chest tightness. Cigarette smoking is the leading cause of COPD. It is estimated that 
over 50% of smokers will develop during the life a chronic respiratory disease (Mannino & 
Buist, 2007). Other than tobacco smoking, risk factors for development of COPD are being 
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increasingly recognised (Soriano et al, 2009) and include environmental factors such as 
occupational exposure to dust and fumes in developed and developing countries (Blanc et 
al, 2009; Soriano et al, 2009) and indoor biomass fuel burning in many developing countries. 
Other environmental risk factors that seem unimportant for development of COPD, but that 
might worsen disease include outdoor pollutants and passive smoke exposure. Therefore, 
adequate monitoring air pollution, accompanied by appropriate strategies for cessation of 
cigarette smoking, are of primary importance for the care of these patients. COPD mainly 
affects middle-aged and older people.  
The prevalence of COPD in the general population is estimated to be about 1% across all 
ages, rising to 8-10% or higher in individuals aged 40 years or older (Soriano et al, 2009). 
Actually is the fourth leading cause of death in the U.S. and is projected to be the third 
leading cause of death for both males and females by the year 2020. The true prevalence of 
this disease within the same population can vary depending on the tool used to identify 
COPD, such as self-reported respiratory symptoms, medical diagnosis, or lung function. The 
correct diagnosis and staging of the disease, based on spirometric functional assessment of 
the patient, are prerequisites for the implementation of rational and therapeutic measures 
with proven effectiveness. The prevention of complications, including through appropriate 
interventions vaccine, along with rehabilitation programs, is critical to positively influencing 
the patient's medical history (GOLD, 2010). 
2. Diagnosis of COPD: From evidence to practice 
In view of the increasing prevalence of the disease around the world, it is tried to create and 
spread worldwide guidelines and programs for the dissemination of current knowledge in 
order to better diagnosis and management of the disease by all health organizations (CTS, 
2008; GOLD, 2010; NICE, 2010; Qaseem et al, 2011). Despite the efforts of implementation of 
existing guidelines COPD remains an underdiagnosed disease and it is poorly treated when 
diagnosed. In population studies, findings show that underdiagnosis of COPD is high and 
independent of overall prevalence (Buist et al, 2007; Soriano et al, 2009). Up to 80% of COPD 
cases remain undiagnosed until the disease is advanced and substantial end-organ damage 
is present (Buist et al, 2007; GOLD, 2010; Price et al, 2010). Furthermore, respiratory disease 
misdiagnosis is common: up to 25% of patients older than 40 years who are labelled as 
having asthma actually have COPD. Conversely, many patients in primary care are labelled 
as having COPD when they have asthma (Jones et al, 2008). It is estimated that there are 
twice as many patients with impaired lung function (indicative of early stage COPD) than 
patients with diagnosed COPD (Price et al, 2010). The symptoms of COPD may be similar to 
those of other respiratory conditions (Table 1) and an accurate differential diagnosis may be 
performed in general practice (GOLD, 2010). 
2.1 Symptoms and questionnaires 
The underestimation of symptoms by the patients is an important problem: despite 
experiencing such symptoms as dyspnoea, chronic cough, or sputum production for months 
or years, patients fail to recognize or report them, believing such symptoms to be a normal 
consequence of smoking, aging or deconditioning (Price et al, 2010; Yawn et al, 2009). 
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Diagnosis   Suggestive features  Recommended investigations 
to confirm diagnosis 
COPD  
 
Onset in midlife; symptoms slowly 
progressive; long history of 
exposure to noxious particles, 
typically tobacco smoking or air 
pollution; dyspnoea during exercise; 
airflow limitation that is not fully 
reversible 
Spirometry confirms presence 
of airflow limitation that is not 
fully reversible 
 
Asthma Onset early in life (often childhood); 
variation in symptoms from day to 
day; symptoms at night or in early 
morning; other atopic conditions 
present (eg, allergy, rhinitis, 
eczema); family history of asthma 
Spirometry confirms presence 
of largely reversible airflow 
limitation  
 
Chronic heart 
failure 
Fine basilar crackles on auscultation CXR shows dilated heart, 
pulmonary edema; spirometry 
confirms restrictive rather than 
obstructive lung disease 
Bronchiectasis Large volume of purulent sputum; 
commonly associated with bacterial 
infection; coarse crackles/clubbing 
on auscultation  
CXR or CT shows bronchial 
dilation, bronchial wall 
thickening 
 
Tuberculosis Onset at all ages; high local 
prevalence of tuberculosis 
CXR shows lung infiltrate; 
microbiological confirmation 
Obliterative 
bronchiolitis 
Onset at younger age in 
nonsmokers; may have history of 
rheumatoid arthritis or fume 
exposure  
CT on expiration shows 
hypodense areas  
Diffuse pan-
bronchiolitis 
Most patients are men and 
nonsmokers; almost all have chronic 
sinusitis  
CXR and HRCT show diffuse 
small centrilobular nodular 
opacities and hyperinflation 
Carcinoma of 
the bronchus 
Symptoms may include dyspnea, 
hemoptysis, coughing wheezing, 
pain in chest or abdomen, cachexia, 
fatigue and loss of appetite; history 
of exposure to carcinogens (such as 
those in tobacco smoke), ionizing 
radiation, or viral infection 
 
CXR; CT; bronchoscopy 
COPD = chronic obstructive pulmonary disease; CXR = Chest radiography;  
CT = computed tomography; HRCT = high-resolution CT. 
Table 1. Differential Diagnosis of COPD (adapted from GOLD, 2010). 
A significant number of patients perceived incorrectly the severity of their disease, based on 
the modified Medical Research Council (MRC) dyspnoea scale (Table 2): 35.8% of subjects 
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with the most severe breathlessness scale and 60.3% of subjects with the next most severe 
scale considered their condition to be mild or moderate (Rodin & Cote, 2008).  
Patient questionnaires are an effective and economic instrument for discriminating between 
subjects with and without COPD (Barnes & Fromer, 2011; Price et al, 2011). Questions 
include items on age, body mass index (BMI), smoking intensity, cough, phlegm, dyspnoea 
on exertion and wheeze, as well as prior diagnosis consistent with asthma or COPD (Table 
3) (Price et al, 2011). Examples of disease-specific instruments include the MRC dyspnoea 
scale (Table 2), the Clinical COPD Questionnaire (CCQ), and the COPD Assessment Test 
(CAT) (Jones et al, 2011). 
 
Grade Degree of breathlessness related to activities 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying on the level or walking up a slight hill 
3 
Walks slower than most people on the level, stops after a mile or so stops after 
15 minutes walking at own pace 
4 
Stops for breath after walking about 100 yds or after a few minutes on level 
ground 
5 Too breathless to leave the house, or breathless when undressing 
Table 2. The MRC Breathlessness Scale (from Bestall et al, 1999) 
2.2 Spirometry 
The diagnosis of COPD has to be confirmed by spirometry (GOLD, 2010; NICE, 2010; 
Qaseem et al, 2011), but in real life, only 30–50% of new cases are confirmed by this 
method (Barnes & Fromer, 2011; Bolton et al, 2005; Joo et al, 2008). Inadequate use of 
spirometry affects not only primary care but also specialised management: analysis of 
medical records of patients admitted to academic tertiary-care hospitals showed that only 
31% of those diagnosed with COPD had spirometry, by contrast with individuals with 
congestive heart failure, of whom 78% had echocardiography, the golden standard 
examination (Soriano et al, 2009). On the contrary spirometry should not be used to screen 
for airflow obstruction in asymptomatic individuals (GOLD, 2010; NICE, 2010; Qaseem et 
al, 2011). 
Spirometry is a reliable, simple, non-invasive, safe, and non-expensive procedure for the 
detection of airflow obstruction. Spirometry can be performed in primary care to assess lung 
function in terms of maximal volume of air forcibly exhaled from the point of maximal 
inspiration [Forced Vital Capacity (FVC)] and the volume of air exhaled during the first 
second of this manoeuvre [Forced Expiratory Volume in 1 s (FEV1)]. It is suggested that a 
postbronchodilator FEV1 < 80% of predicted, together with a FEV1/FVC ratio of < 0,7, is 
indicative of airflow limitation that is not fully reversible (GOLD, 2010; NICE, 2010; Qaseem 
et al, 2011.)  
A basal spirometry, without bronchodilator, has been shown to lead to overdiagnosis of 
COPD by 11% in primary care (Jones et al, 2008) and by 27% in screening studies 
(Johannessen et al, 2005). The impairment of FEV1 in COPD is partially related to symptoms 
and disease severity. For this reason the main COPD guidelines define FEV1 thresholds for 
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classifying stages of disease severity (table 4). The classifications are not all the same because 
the correlation between FEV1 values and clinical manifestations of COPD are not well 
defined. In 2012 the new GOLD guidelines will propose a new COPD severity classification, 
which will be based not only on spirometric evaluation but also on symptoms intensity and 
exacerbations frequency. However, after a medical diagnosis of COPD, guidelines (GOLD, 
2010) recommend that patients should undergo a spirometry follow-up every 6 months or 
yearly. The assessment of sequential spirometry values in COPD is important because the 
Lung Health Study showed significant differences between individuals who continued to 
smoke (they lost 63 mL of their FEV1 per year) versus non-smokers (-30 mL of FEV1 per 
year) (Anthonisen et al, 2002b). 
 
 Response choices Points* 
What is your age? 40-49 years 0 
50-59 years  5 
60-69 years 9 
How many pack years of cigarettes have you smoked? 0-14 pack years 0 
15-24 pack years 3 
25-49 pack years 7 
50 + pack years 9 
Have you coughed more in the last few years? yes 0 
no 1 
During the past 3 years, have you had any breathing 
problems that have kept you off work, indoors, at home or in 
bed? 
Yes 0 
no 3 
Have you ever been admitted to hospital with breathing 
problems? 
yes 6 
no 0 
Have you been short of breath more often in the past few 
years? 
yes 1 
no 0 
On average, how much phlegm (sputum) do you cough up 
most days? 
None or less than  
1 tablespoon  
(15 ml) 
0 
or more per day 4 
If you get a cold, does it usually go to your chest? yes 4 
no 0 
Are you taking any treatment to help your breathing?  yes 5 
no 0 
*Scoring system: Add up the total number of points based on the patient’s response. 
18 or fewer points suggests a diagnosis of asthma; 19 or more points suggests a diagnosis of 
COPD 
Table 3. Differential diagnosis questionnaire to determine between COPD and asthma 
(adapted from Price et al, 2011) 
The International Primary Care Respiratory Group (IPCRG) currently recommends a case 
identification spirometry in all patients over 35 years who present with respiratory 
symptoms and risk factors, such as prior or current smoking history (Decramer et al, 2011; 
Levy et al, 2006; NICE 2010). Spirometry undertaken at the primary-care level aims to 
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exclude individuals with normal lung function and to identify those who need a complete 
investigation for COPD (Figure 1).  
 
Stage CTS 2008 NICE 2010 GOLD 2010 ACCP, ACP, 
ATS, ERS 
(Quaseem, 2011) 
I - Mild >= 80 >= 80 >= 80 > 80 
II - Moderate 79,9-50 79,9-50 79,9-50 80-60 (> 50) 
III - Severe 49,9-30 49,9-30 49,9-30 < 60 
IV - Very severe <30 <30 <30 
Table 4. FEV1 thresholds (% of theorical values) for classification of COPD 
 
Fig. 1. Screening strategies for COPD (modified from Soriano et al, 2009) 
However, spirometry is not commonly performed in primary care practice for many 
reasons, including limited access, lack of training, cost and time constraints (Barnes & 
Fromer, 2011; Perez et al, 2011). Spirometric results need a clinical interpretation, with a 
minimum time commitment of 2–10 min. Interpretation of one value should be assessed in 
conjunction with many others and by review of the shape of the best curves (ie, flow-volume 
loops and timing) (Soriano et al, 2009). An English survey find that most of the general 
practices in UK have a spirometer (82.4%) and use it (85.6%), but confidence in use and 
interpretation of results varied widely: 58.1% are confident in use but only 33.8% are 
confident in values interpretation (Bolton et al, 2005). A Swiss survey evaluated that 
spirometries in general practice are of acceptable quality with reproducible data in 60% of 
measurements (Leuppi et al, 2010). On the contrary a Dutch study (Schermer et al, 2003) 
assessed that the proportion of non-reproducible tests was 16% for laboratory tests and 18% 
for general practice tests in the first year, and 18% for both in the second year of evaluation, 
confirming that validity and quality of spirometric tests in general practice were as 
satisfactory as the procedure performed in the same group of COPD patients in a 
pulmonary function laboratory. 
Adherence to the guidelines on the use of spirometry for diagnosis and follow-up is quite 
different in countries and often not comparable. A recent study (Chavez & Shokar, 2009) has 
estimated that only 50% of patients diagnosed with COPD performed a functional testing to 
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confirm the presence of bronchial obstruction and only 40%, once diagnosed, received 
appropriate treatment. The adherence to GOLD guidelines by primary care providers have 
been recently evaluated (Perez et al, 2011): the study showed that less of 60% of general 
practitioner (GPs) complied with at least 5 to 7 key recommendations of the GLs used for 
evaluation. Cazzola, using an italian database in general practice, observed that a COPD 
population, registered in a period of 10 years, had a prevalence of chest radiograph in 67.7% 
while in the same period only the 31.9% of the patients had a spirometry (Cazzola et al, 
2009). An important barrier to adherence is constituted by the lack of familiarity with 
specific recommendations due to the inadequate training in the management of COPD. In 
addition, medical students complain of inadequate training in the interpretation of 
spirometric tests (Perez et al, 2011; Soriano et al, 2009). 
2.3 Radiology 
There are no specific features of COPD on a plain chest radiograph. The features which are 
usually described are those of lung overinflation, vascular changes and bullae. However, 
even in patients with very appreciable disability, chest radiography results may be normal 
(Simon et al, 1973). The accuracy of diagnosing emphysema by plain chest radiography 
increases with the severity of the disease and it has been reported as being 50–80% accurate 
in patients with moderate-to-severe disease (Remy-Jardin et al, 1993). Modern imaging 
techniques, particularly with the advent of CT and, more recently, high resolution CT 
(HRCT), have provided a more sensitive means of diagnosing macroscopic emphysema 
during life (Gevenois & Yernault, 1995; Klein et al, 1992).  
3. Treatments for stable COPD 
The pharmacological treatment of COPD is based on the severity of the disease, defined by 
functional impairment and frequency of exacerbations (CTS, 2008; NICE, 2010; GOLD, 2010;  
 
Fig. 2. Effects of smoking and smoking cessation on decline in lung function among adults 
with COPD (modified from Jones & Østrem, 2011).  
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Qaseem et al, 2011). It is currently under definition an algorithm that takes into account 
the intensity of symptoms, assessed with different scales (MRC and CAT). Smoking 
cessation is the first therapeutic measure, and perhaps most important in changing the 
natural history of disease. As it has been well demonstrated (Anthonisen et al, 2002a; 
Fletcher & Peto, 1977; Jones & Østrem, 2011) smoking cessation significantly improves 
survival, including the reduction of the pulmonary function decay. The relationship 
between long-term cigarette smoking, decline in lung function (FEV1 reduction) and life 
expectancy was demonstrated by Fletcher & Peto in 1977, but recently Jones &  
Østrem (2011) have redrawn the curves (Figure 2) to take into account data from recent 
studies. 
3.1 Treatment strategies with inhaled drugs and COPD severity 
The therapeutic approach to stable COPD is progressive, in steps, in relation to the 4 levels 
of severity defined by all guidelines (GLs) (CTS 2008; NICE, 2010; GOLD, 2010; Qaseem et 
al, 2011). As an example, the treatment schedule proposed by GOLD GLs (2010) is reported 
in figure 3. 
 
Fig. 3. COPD treatment strategies proposed by GOLD GLs (2010 – modified)  
 Stage 1 (mild COPD): Initially, the drug treatments are based on the use to need of 
short-acting bronchodilators (in particular beta2-agonists with short duration of action - 
SABA). Some GLs (NICE, 2010; GOLD, 2010) suggest starting to use a long-acting 
bronchodilator (LABA or tiotropium) if symptoms (including cough and dyspnoea) are 
not well controlled with SABA. 
 Stage 2 (moderate COPD): All recent GLs (CTS, 2008; NICE, 2010; GOLD, 2010; Qaseem 
et al, 2011) agree in recommending the use of a long-acting bronchodilator alone (LABA 
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or tiotropium) as first choice. If the symptoms persist or in the presence of frequent 
exacerbations (2 or more in the previous year) it is recommended to combine LABA and 
tiotropium and sometimes even an inhaled corticosteroid (ICS). 
 Stage 3 (severe COPD): All recent GLs (CTS, 2008; NICE, 2010; GOLD, 2010; Qaseem et 
al, 2011) agree in recommending the use, as first choice, of a long-acting bronchodilator 
alone (LABA or tiotropium) and, in case of ineffectiveness, of associating LABA and 
tiotropium. The introduction of an ICS, usually associated with a LABA in a fixed 
combination, should be reserved for patients who have frequent exacerbations (at least 
2 or more in the previous year).  
 Stage 4 (very severe COPD): Treatment strategy is the same as Stage 3, although the 
introduction of an ICS, or the simultaneous use of LABA + ICS + tiotropium (Triple 
association) is from an early diagnostic findings (Karner & Cates 2011). 
3.2 Efficacy of Inhaled treatments for COPD 
In recent years the inhalation therapy of COPD has been shown to be effective in reducing 
symptoms, the frequency and severity of exacerbations, improve health status and exercise 
tolerance (NICE, 2010; GOLD, 2010; Spencer et al, 2011). In severe cases the only fixed 
combination of LABA and ICS, given twice a day and for several years, has also been shown 
to reduce mortality compared to placebo (Baker et al, 2009; Kliber et al, 2010; Nannini et al, 
2007a; Wilt et al, 2007). However, the benefit is very modest, so that combination therapy 
(LABA + ICS, with or without tiotropium) does not appear to significantly improve 
clinically important outcomes (such as mortality, hospitalizations, severe exacerbations) 
than treatment with single products (Baker et al, 2009; Kliber et al, 2010; Nannini et al, 
2007b; Puhan et al, 2009; Rodrigo et al, 2009; Welsh et al, 2010; Wilt et al, 2007). The 
association between LABA and tiotropium does not demonstrate advantages when 
compared with tiotropium alone (Wang et al, 2011). 
The choice of the drug to start with, and any subsequent associations has to be customized, 
since the relationship between the severity of symptoms and the severity of airflow 
obstruction is influenced by other factors, such as the frequency and severity of 
exacerbations, presence of one or more complications, respiratory failure, comorbidities 
(cardiovascular disease, sleep disorders, etc.) and general health. 
Fundamental to the effectiveness of prescribed treatments is that the patient has been 
properly teached on how to use various devices inhalers (Al-Showair et al, 2007; Dolovich et 
al, 2011). Patients with COPD may have problems in coordination and find it difficult to use 
a metered-dose inhaler (MDI) or, in cases of severe emphysema, fail to produce the 
inspiratory depression (Peak Inspiratory Flow - PIF) required to inhale the powder of a 
device DPI (Dry Powder Inhaler). The inhaler technique should be checked at each visit (see 
Table 5). 
Many drugs are available for nebulising to be used in patients who have very low 
inspiratory flow (PIF), i.e. for severe hyperinflation. However, there are few randomized 
studies on their benefits compared to many other devices, and the use of nebulizers often 
depends on personal preferences, the availability and price. The nebulizer treatment should 
be continued only if patients report a clear benefit on symptoms. 
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Metered dose inhalers (MDI) Dry powder inhalers (DPI) 
 Load the dispenser 
Exhale away from device Exhale away from device 
Put mouthpiece in your mouth Put mouthpiece in your mouth  
Take a slow, deep breath at the same time 
you press down on the medication canister. 
Take a deep breath and breath in quickly. 
 
Continue inhaling slowly for 4-5 seconds Hold your breath for 10 second or as long 
as possible. 
 Do not exhale through the mouthpiece to 
avoid wetting the chamber. 
At the end of inhalation always rinse the mouth. 
Table 5. Patient information for optimal use of inhaled devices  
(adapted from Dolovich et al, 2011) 
3.3 Safety of Inhaled treatments for COPD 
β2-agonists. The β2-adrenergic receptors stimulation can give sinus tachycardia at rest and 
induce changes in heart rate in patients highly susceptible. A recent review of the literature 
has also ruled out that prolonged treatment with LABAs increase the risk of cardiovascular 
death (Rodrigo et al, 2008). In older patients treated with high doses of β2-agonists can occur 
over a tremor that creates problems, regardless of the administration route, thus limiting the 
tolerated dose. Other metabolic effects, subject to tachyphylaxis, are hypokalaemia, 
especially when the beta2-agonist therapy is associated with a thiazide diuretic (Lipworth et 
al, 1990), and the increase of oxygen consumption at rest (Uren et al, 1993). 
Anticholinergics. Inhaled anticholinergic drugs are poorly absorbed, which limits the 
occurrence of important systemic adverse effects (AEs), that are atropine-like (Tashkin, 
2010). The most common AE is dry mouth. Some patients using ipratropium report a bitter 
and metallic taste. It has rarely been reported prostate (dysuria, urinary retention) and 
ocular (worsening of acute glaucoma) disorders. A slight increase in cardiovascular events 
compared with placebo, was observed in COPD patients regularly treated with ipratropium 
(Anthonisen et al, 2002b; Michele et al, 2010) or tiotropium used with Respimat MDI device, 
(a death in every 124 patients treated per year) (Singh et al, 2011). 
Inhaled corticosteroids. Inhaled steroids in COPD are used almost exclusively associated 
with LABAs and at doses lower than those used in the treatment of asthma in adults. There 
are adverse events (AEs) both local and systemic: 
 Topic AEs (oral candidiasis, dysphonia and pharyngitis): affect 8-10% of patients and 
the frequency increases by increasing the administered dose (Rachelefsky et al, 2007). 
Typically there is a lower incidence of AEs using DPI formulations compared to MDI 
formulations. The risk of such AEs can be reduced by rinsing the mouth after 
inhalation. 
 Systemic AEs: the most important are the increased frequency of pneumonia and 
fractures. An increased frequency of pneumonia and severe pneumonia (respectively 
+2.7% and +2.1%), without increasing total mortality, has been documented with ICS 
treatment, alone or in combination with LABAs (Singh et al, 2009). The risk of 
pneumonia increases especially in patients with more severe COPD (FEV1 <40%). A 
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modest increase (+0.3%) in the risk of bone fractures related to the dose of ICS has been 
recently documented in a systematic review of 16 randomized controlled trials with 
17,513 patients affected with moderate to severe COPD (Loke et al, 2011). In prolonged 
treatments with high doses of ICS were also reported cases of adrenal cortical 
insufficiency, cataracts, glaucoma and dermal dystrophy (thinning skin, easy bruising). 
(Tashkin et al, 2004). 
3.4 Oral treatments for COPD 
Methylxanthines (theophylline). The most commonly used methylxanthine is theophylline, 
whose clearance decreases with age. Low-dose theophylline reduces exacerbations, but do 
not improve post-bronchodilator lung function (Zhou et al, 2006). The evidence supporting 
the use of theophylline in stable COPD, limited because of its side effects, is insufficient. The 
toxicity of theophylline is dose-dependent, the therapeutic index is low and most of the 
benefits appear only with the administration of doses close to those toxic (Ram, 2006b). The 
AEs include the development of atrial and ventricular arrhythmias (which can be fatal), 
grand mal seizures (which may occur regardless of a previous history of epilepsy). Other 
AEs include headache, insomnia, nausea and epigastralgia, which can also occur within the 
therapeutic range of theophylline. Methylxanthines also have significant interactions with 
commonly used medications, such as digitalis, warfarin, etc.. 
Phosphodiesterase-4 inhibitors (roflumilast). The main activity of the inhibitors of 
phosphodiesterase-4 (PDE4 inhibitors) is to reduce inflammation by inhibiting intracellular 
cyclic AMP degradation (Rabe, 2011). The use of roflumilast is not worldwide approved. 
This drug is administered orally once a day, without direct bronchodilator activity, although 
it has been shown to improve FEV1 in patients treated with tiotropium or salmeterol 
(Calverley et al, 2009; Fabbri et al, 2009). In patients with severe to very severe COPD and a 
history of exacerbations, the roflumilast is able to reduce moderate and severe exacerbations 
(Calverley et al 2009; Rabe, 2011). There is a lack of evidence for comparing roflumilast vs or 
added to inhaled corticosteroids. The PDE4 inhibitors cause more AEs than inhaled 
medications for COPD (Calverley et al, 2009; Fabbri et al, 2009; Rabe, 2011). The most 
frequent AEs are nausea, decreased appetite, abdominal pain, diarrhoea, headache and 
sleep disorders; these AEs seem to occur early during treatment, are reversible and reduced 
over time during continued treatment. Since in registrative clinical trials was seen a decline 
in average weight of 2 kg in patients treated with roflumilast, the drug is not recommended 
in patients underweight. Roflumilast should be used with caution in patients with 
depression, too. The roflumilast and theophylline should not be administered concurrently. 
3.5 Oxygen therapy 
The long-term oxygen therapy (LTOT) is usually administered in patients with stable COPD 
who have: 
 PaO2 equal to or less than 7.3 kPa (55 mmHg) or SaO2 equal to or less than 88%, with or 
without hypercapnia or 
 PaO2 between 7.3 kPa (55 mmHg) and 8.0 kPa (60 mmHg), or SaO2 > 88%, if there is 
pulmonary hypertension, peripheral edema suggesting congestive heart failure, or 
polycythemia (hematocrit > 55%). 
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LTOT has been shown to increase survival in patients with chronic respiratory failure and 
severe hypoxemia at rest only if practiced over 15 hours a day (Stoller et al, 2010). 
Oxygen therapy can be administered in three ways (ATS, 1995; Celli & McNee, 2004):  
 Long-term continuous therapy, 
 during physical exertion and 
 to relieve acute dyspnoea. 
The main goal of oxygen therapy is to increase the baseline PaO2 to a minimum of 8.0 kPa 
(60 mmHg) at sea level and at rest, and / or produce an O2 saturation of at least 90%. 
Oxygen is usually released through face masks, with adequate flow concentrations, ranging 
from 24 to 35%. The facemask get an accurate titration of oxygen; however, many patients 
prefer the oxygen released by nasal cannula. The release of oxygen by this route requires 
additional monitoring of blood gases to ensure a satisfactory oxygenation, and may require 
individual titration. Additional oxygen at home is usually the most expensive part of the 
therapy of patients with COPD (Petty & O’Donohue, 1994). The oxygen concentrators can be 
cheaper than the systems of delivery of liquid or gaseous oxygen (Heaney et al, 1999). 
3.6 Non-pharmacologic treatments for stable COPD 
Vaccinations. The annual flu vaccination has been shown to reduce both hospitalizations 
and mortality in patients with COPD (Nichol et al, 1999a; Poole et al, 2006). Pneumococcal 
vaccination has been shown to produce important benefits, such as the reduction of 
hospitalizations and total mortality, particularly in patients with severe COPD (Nichol et al, 
1999b). 
Pulmonary Rehabilitation The main goals of pulmonary rehabilitation are to reduce 
symptoms, improve quality of life and increased physical and emotional participation in 
everyday activities (Nici et al, 2006; Ries et al, 2007). 
The minimum length of an effective rehabilitation period is 6 weeks, but better results are 
obtained with activities even longer. However, no effective program has been developed so 
far to maintain the effects over time (Ries et al, 2007). Although the benefits have not been 
studied, it is reasonable to suggest to COPD patients, who can not follow a structured 
rehabilitation program, to exercise on their own (such as walking for 20 minutes a day). In 
any case, patients with more severe dyspnea (stage MRC 4 - see table 2 ) may not have the 
benefit of rehabilitation (Wedzicha et al, 1998) 
The components of pulmonary rehabilitation programs are: 
 Physical training. The exercise tolerance can be assessed with various tests, the 
simplest of which is the 6-minute walking test, measuring the distance traveled. The 
duration of physical training generally ranges from 4 to 10 weeks, resulting in greater 
effects for longer than the shorter lengths (Lacasse et al, 1996). The patient should be 
encouraged to move until it has been completed a walking period of 20 minutes. In 
patients severely disabled, the use of a simple walker with wheels improves walking 
distance and decreases the sensation of dyspnoea. The addition of upper limb exercises 
or other aerobic training is effective in improving the muscular strenght, but does not 
improve the quality of life or exercise tolerance (Bernard et al, 1999). 
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 Smoking cessation. Smoking cessation has the greatest impact on the natural history of 
COPD (figure 2). The evaluation of smoking cessation in a multicenter, long-term study 
(Anthonisen et al, 1994) indicates that, if effective resources and time are devoted to 
smoking cessation, can be maintained long-term quit rate of 25%.  
 Nutritional counselling. Nutritional status is an important part of certain symptoms, 
disability and prognosis of COPD. Both overweight and underweight can be a problem 
(Nici et al, 2006). Approximately 25% of patients with COPD shows a reduction in body 
mass index, especially against the lean mass, which turns out to be an independent risk 
factor for mortality (Schols et al, 1998). The current evidence suggests that the 
nutritional supplement alone may not be sufficient if a strategy is not associated with 
exercise. In patients with COPD, nutritional supplements (eg creatine) do not 
substantially increase the training effect of a multidisciplinary pulmonary rehabilitation 
program (Deacon et al, 2008). Anabolic steroids in COPD patients with weight loss 
increase body weight and lean body mass, but have little or no effect on exercise ability 
(Weisberg et al, 2002). 
 Education. Most pulmonary rehabilitation program includes an educational 
component, but the specific contributions of education to the improvements obtained 
after pulmonary rehabilitation are still not clear. Patient education alone does not 
improve exercise performance or lung function, but may play a role in improving the 
skills, the ability to cope with the disease and health status (Celli, 1995). 
Table 6 summarizes the benefits of pulmonary rehabilitation in descending order with 
respect to the robustness of available evidences (from A to C grading system). 
Grading*  
A Improves the ability to exercise 
A Reduces the intensity of the perceived sense of breathlessness 
A Improves the quality of life related to health 
A Reduces the number and days of hospitalisation 
A Reduces anxiety and depression associated with COPD 
B 
Strength and endurance training of the upper limbs improves the function of 
the arms. 
B The benefits extend beyond the immediate period of training 
B Improves survival 
B Increases the effect of long-acting bronchodilators 
B Improves recovery after hospitalisation for an exacerbation 
C 
Training of respiratory muscles is useful, especially when combined with 
physical training 
C Psychosocial intervention is helpful 
*The grading system express the robustness of scientific evidence: an A recommendation is sustained by 
a strong scientific proofs, while a D evidence is mainly based on expert-opinion. Grade B and C express 
intermediate levels of evidence. 
Table 6. Benefits of pulmonary rehabilitation in patient with COPD  
(modified from GOLD GLs, 2010) 
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4. COPD and comorbidity  
COPD often coexists with other diseases that have a significant impact on prognosis (Barnes 
& Celli, 2009; Mannino et al, 2008; Soriano et al, 2005; Sin et al, 2006). Some of these more 
often coexist and may be correlated, both for shared risk factors that impact on the mutual 
development (Fabbri et al, 2008), although the risk of comorbidity may also be the result of 
consequences of COPD, for example, reduced physical activity. 
Cardiovascular disease is probably the main comorbidity in COPD (Fabbri et al, 2008; 
Soriano et al, 2005). Heart Failure (HF) is common in COPD: about 30% of patients with 
stable COPD have some degree of HF (Rutten et al, 2005). Worsening of HF is a significant 
differential diagnosis to an acute exacerbation of COPD. About 30% of patients in a 
cardiologic clinic is diagnosed with COPD (Hawkins et al, 2009) which will often be the 
cause of hospitalization for acute HF, with significant implications on prognosis (Iversen et 
al, 2010). In the treatment of HF with concomitant COPD is preferable to use a β-selective 
blocker (β-1 selective) compared to a non-selective β-blocker (Jabbour et al, 2010). Patients 
with COPD also have an increased incidence of Atrial Fibrillation (AF) (Buch et al, 2003). 
There are no reliable data on the use of drugs in COPD patients with AF and these patients 
were often excluded from clinical trials. In cardiac patients, however, it seems reasonable to 
avoid particularly high doses of β-agonists. 
Other diseases commonly associated with COPD are osteoporosis (often under-diagnosed 
and at risk of deterioration with the use of systemic corticosteroids) and depression 
(associated with poor prognosis, but can favorably affected by exercise rehabilitation - 
Knubben et al, 2007). Lung cancer is often observed in patients with COPD and was found 
to be the most frequent cause of death in patients with mild COPD (Anthonisen et al, 2002a). 
5. Management of acute exacerbations of COPD (AECOPD) 
An authoritative definition of acute exacerbation of COPD (AECOPD) is the American 
Thoracic Society (ATS)/European Respiratory Society (ERS) consensus statement one: "an 
exacerbation of COPD is an event in the natural course of the disease characterised by a 
change in the patient’s baseline dyspnoea, cough and/or sputum beyond day-to-day 
reliability sufficient to warrant a change in management" (Celli & McNee, 2004). 
On average, COPD patients have one to four AECOPD per year, of various 
intensity/severity (Hagedorn, 1992). Patients who have frequent exacerbations (more than 3 
per year) have a more rapid decline in lung function than patients who relapsed less 
frequently (-40 mL FEV1/year vs. -32 mL FEV1/year) (Donaldson et al, 2002). The economic 
burden of this common condition is extremely high, taking into consideration that during an 
AECOPD there is an intensification of treatment and often the need for hospitalisation, or 
even use of the intensive care unit (ICU). Hospital mortality for AECOPD is about 10% per 
year (Siafakas & Wedzicha, 2006) and the long-term outcome is rather poor: 3 years after 
hospitalization mortality from all causes rises up to 49% (Gunen et al, 2005; Wouters, 2003).  
5.1 Diagnosis of AECOPD 
The diagnosis of COPD exacerbation is clinical and does not depend on the results of ad hoc 
surveys, however, such investigations may help to define an optimal strategy of treatment. 
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The presence of greenish phlegm is a good indicator of high bacterial load and the potential 
success of antibiotic therapy; patients with light-colored phlegm do not derive additional 
benefit from antibiotic treatment (Stockley et al, 2000). Pulse oximetry may be useful in 
assessing the severity of an exacerbation and to identify patients who may benefit from 
oxygen (Bach et al, 2001). Chest radiographs are useful in the differential diagnosis, 
distinguishing pneumonia, congestive heart failure, pneumothorax, pleural effusion , etc. 
(Emerman & Cydulka 1993; Sherman et al, 1989; Tsai et al, 1993). During an exacerbation, 
lung function changes are usually limited , then spirometry takes little diagnostic 
significance (Bach et al, 2001).  
5.2 Causes of AECOPD 
For adequate management of the patient it is of paramount importance to identify the 
causes of AECOPD (Celli & McNee, 2004; GOLD, 2010) (Figure 4); however, in 
approximately one-third of the cases, this is not feasible. In more than half of the episodes, 
the cause of an exacerbation is a viral infection. Bronchoscopic studies have shown that at 
least 50% of patients have bacteria in high concentrations in their lower airways during 
exacerbations of COPD (Pela et al, 1998), but a significant proportion of these patients have 
bacteria in their lower airways in the stable phase of the disease, too (Sethi & Murphy, 2008). 
Conditions that may mimic the symptoms of an COPD exacerbation in a patient with COPD 
include pneumonia, congestive heart failure and/or arrhythmias, pulmonary embolism, 
pneumothorax, pleural effusion, metabolic diseases, inappropriate use of drugs (hypnotics) 
or end-stage disease (Siafakas & Wedzicha, 2006).  
 
Fig. 4. Etiology of AECOPD (modified from Anzueto, 2010) 
5.3 Home management of AECOPD 
Proper decision about the management of an AECOPD requires information on the previous 
condition of the patient in the stable state and a precise assessment of the severity of the 
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present episode (Celli & McNee, 2004; GOLD 2010). In table 7 the factors to consider to 
decide whether to manage an AECOPD at home or in hospital are reported (NICE, 2010).  
 
 Treat at home? Treat in hospital? 
Able to cope at home Yes No 
Breathlessness Mild Severe 
General condition Good Poor/deteriorating 
Level of activity Good Poor/confined to bed 
Cyanosis No Yes 
Worsening peripheral oedema No Yes 
Level of consciousness Normal Impaired 
Already receiving LTOT No Yes 
Social circumstances Good Living alone/not coping 
Acute confusion No Yes 
Rapid rate of onset No Yes 
Significant comorbidity (particularly 
cardiac disease and insulin-dependent 
diabetes) 
No Yes 
SaO2 < 90% No Yes 
Table 7. Patient’s factors to consider when deciding where to manage an AECOPD 
(modified from NICE, 2010) 
A review shows that, when the patient does not require intensive hospital care and can be 
adequately cared at home, the home management of exacerbations is effective as the 
hospital management (mortality and hospital readmissions are similar) (Ram et al, 2004) and 
is most appreciated by patients and carers. The objectives of outpatient or home 
management are (Hurst & Wedzicha, 2004; Ram et al, 2004): 
 educate patients and families on the signs of deterioration and the actions to be taken 
(with written instructions); 
 increase maximum airflow;  
 remove excess bronchial secretions;  
 treat infection, if present;  
 improve respiratory muscle strength and, thus, facilitate cough;  
 avoid or monitor adverse events of treatment. 
A decisional algorithm to facilitate decisions in treating at home a mild to moderate 
AECOPD exacerbation is reported in figure 5 (modified from Siafakas & Wedzicha, 2006). 
Education: it was shown that education can reduce utilisation of health services and result 
in better survival rates after an AECOPD (Nici et al, 2006; Tougaard et al, 1992). Educational 
intervention (better with written instructions) should underline the following features:  
 The patient, but just as importantly the family, should be instructed on the signs and 
symptoms that indicate a worsening of the patient’s condition and the actions that 
should be taken, e.g. contact a physician or go to the hospital. 
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 Self-clearance of sputum by frequent coughing and/or by performing forced expiratory 
manoeuvres from middle lung volume. An effective cough consists of a slow, deep 
inspiration, a few seconds of breath holding followed by a cascade of two to three 
voluntary cough efforts.  
 If the patient is on LTOT, advise him/her not to change the dose by him/herselve; 
 Adequate training in usage of treatment to ensure maximum compliance to prescribed 
treatment.  
 Usual nutrition may need to be modified (i.e. small and frequent meals with low 
carbohydrate content) and fluid intake increased.  
 Advise the patient or his/hers family to avoid sedatives and hypnotics, as well as 
cough mixtures that contain such agents. 
 
Fig. 5. Algorithm for the home management of an AECOPD  
(Modified from Siafakas & Wedzicha, 2006)  
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Bronchodilators (short acting and long acting): increasing doses of beta 2 agonists "short 
acting" (isoprenaline, salbutamol, terbutaline) may effectively counteract the increased 
dyspnoea; standard pressurized inhalers (MDI) and nebulizers are equally effective dose 
inhalers to administer bronchodilators; doses to be administered and the patients’ 
conditions may influence the choice of method of administration (see table 5). There is no 
evidence on the effectiveness of LABAs in the treatment of exacerbations. The use of 
ipratropium or tiotropium (alone or in combination) does not appear justified in the first 
instance (McCrory & Brown, 2003). 
Inhaled and Oral Corticosteroids: Initiating or increasing the dose of inhaled 
corticosteroids (ICS) is the first step-up when steroid treatment is required. If a spacer is 
used and an adequate dose is given, this mode of administration (inhaled) is efficient in 
most cases. However, oral corticosteroids may be needed in more severe cases, often with 
beneficial results (Thompson et al, 1996; Siafakas & Wedzicha, 2006). A daily dose of 30–40 
mg of prednisolone for 10–14 days may be required. Systemic corticosteroids shorten the 
length of hospital stay, improve lung function (FEV1) and arterial hypoxemia (PaO2) (Davies 
et al, 1999, Maltais et al, 2002; Thompson et al, 1996); they also reduce the risk of early 
recurrence and treatment failure (Aaron et al, 2003; Davies et al, 1999). 
Antibiotics: although only half of AECOPD are due to infections, and a large part of these 
are viral (Wedzicha, 2004), it is common practice to administer a course of antibiotics for 7–
14 days. A systematic review of the few placebo-controlled studies available has shown that 
antibiotics reduce the risk of short-term mortality by 77%, by 53% of the treatment failure 
and sputum purulence by 44%. This review supports antibiotics for patients with moderate 
or severe AECOPD, with increased cough and sputum purulence (Quon et al, 2008; Ram et 
al, 2006a). The benefits of antibiotics are still more pronounced in patients with more severe 
exacerbations (Bach et al, 2001). 
The local bacterial resistance should be taken into account when empirical treatment is 
given (Celli & McNee, 2004). Broad-spectrum antibiotics, such as amoxicillin, with or 
without clavulanic acid, tetracyclines, erythomycin or oral cephalosporin are recommended 
(Siafakas et al, 2005). In particular conditions (patients with frequent episodes of 
exacerbation, recent antibiotic treatments or hospitalizations, stays at facilities for the 
elderly) is likely the selection of multiresistant (bacterial strains especially Pseudomonas or 
Staphylococcus aureus). In these cases, when the targeted therapy is not possible, you 
should choose between fluoroquinolones or cephalosporins (Woodhead al, 2005). 
Mucolytic agents: recent guidelines conclude that: "there is no evidence to support 
prescription of mucolytics in acute exacerbation". However, these agents can be beneficial in 
a few cases with copious and tenacious sputum (Celli & McNee, 2004; GOLD, 2010). 
Oxygen therapy: Initiation of oxygen therapy at home during an exacerbation of COPD may 
lead to serious complications and should be avoided. If the patient is on long-term oxygen 
therapy (LTOT), a thorough inspection of the apparatus and dosage of oxygen administered 
is recommended (see paragraph 3.5). In addition, a clinical evaluation of adequate 
oxygenation is required. However, when the evaluation is in doubt, the assessment should 
take place in the hospital with emogasanalysis. (Siafakas & Wedzicha, 2006; NICE 2010). 
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5.4 Hospital discharge and follow-up 
The following features were found to be predictive of re-hospitalization (Bahadori & 
Fitzgerald, 2007): a previous hospitalization, use of oral corticosteroids or long-term oxygen, 
the poor quality of life associated with reduced physical activity. Regular home visits by a 
community nurse may permit earlier discharge of patients hospitalized for AECOPD 
without increasing re-hospitalizations (Celli & McNee, 2004; Hermiz et al, 2002; Hughes et 
al, 2000; Siafakas et al, 2005). However, the exact criteria for this approach remain uncertain 
and vary depending on the scope rated health (Hermiz et al, 2002). The use of a written 
action plan increased therapeutic interventions appropriate for an acute exacerbation, an 
effect that does not diminish, however, the use of health resources (Wood-Baker et al, 2006). 
For patients who are hypoxemic during the AECOPD, blood gases and / or pulse oximetry 
should be reevaluated before hospital discharge and if the patient remains hypoxemic, it 
may be necessary to add an additional long-term oxygen therapy.  
5.5 Prevention of AECOPD 
Smoking cessation, anti-flu and anti-pneumococcal vaccines, knowledge of current 
treatment, including inhaler technique, the constant treatment with inhaled bronchodilators 
in long duration of action, with or without inhaled corticosteroids, significantly reduces the 
number of exacerbation and hospitalization (Calverley et al, 2007; Nannini et al, 2007a; 
Nannini et al, 2007b; Tashkin et al, 2008). Early outpatient pulmonary rehabilitation after 
hospitalization is safe (see paragraph 3.6) and leads to significant clinical improvements in 
terms of exercise capacity and health status at 3 months (Man et al, 2004). If the patient has a 
significant persisting disability should be evaluated in social welfare issues, identifying the 
main caregivers with whom agree the treatment plan. 
6. Conclusions 
COPD is a chronic disease whose prevalence is increasing, and the diagnosis and 
management is primarily the task of general practitioners. Screening for COPD is not 
recommended in asymptomatic smokers, but running an office spirometry in heavy 
smokers older than 35 years and with symptoms can be an initial framework for early 
detection of COPD and provide effective interventions to reduce mortality. Smoking 
cessation has been shown to improve the prognosis of patients with COPD, especially if 
applied early. Treatments with combined inhaled LABA and ICS have also been shown to 
reduce mortality in patients with more severe COPD, while the use of long-acting 
bronchodilators (LABAs or/and tiotropium) reduces only the number of exacerbations and 
hospitalizations. Pulmonary rehabilitation is a key to improving treatment outcomes 
(important for patients with COPD), but is rarely used, especially in home management of 
COPD. Able to prevent or control the AECOPD at home is a very important goal of the GP, 
for which it is necessary to apply the recommendations of the best guidelines and obtain the 
cooperation of patients and their families. 
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